Back to News
Activism

Activist Investing Today: Evercore’s Lin Eyes White Squire Double-Edged Sword

|
Published: October 20th, 2023
Managing director Gloria Lin, who focuses on strategic defense and shareholder advisory, discusses the pros and cons of defense PIPE infusions, governance and M&A insurgencies.

White squire PIPE investments can be a “potentially attractive” defense against an activist agitating against a deal or running a campaign at a company, Evercore Inc. managing director Gloria Lin said on the latest Activist Investing Today podcast.

More often than not, however, Evercore “cautions against” taking a PIPE investment when facing an activist.

“Unless there is a clear business purpose, such as to fund M&A or to fund R&D, it is hard to justify the need, really for all your shareholders,” Lin said. “That’s not to say we haven’t had clients in the past that have actually implemented a PIPE when there have been activists involved.”

She added that PIPE investments from well-known PE investors can give a “stamp of approval” for value creation at the company, but corporations should be aware that a friendly PIPE investor “might not be quite as supportive of the strategy” down the road.

Beyond white squire infusions, Lin discussed governance, so-called “bad deals” and trends in M&A activism amid a cooling deal market.

Check out the podcast with Gloria Lin below:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com

More From Activism

Activism

Activist Investing Today: Eldar on Anti-Activist Pill Evolution

By Ronald Orol
|
Published: May 23rd, 2025
When corporations install anti-activist poison pills they're less likely to implement new share buybacks and their operationally focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.
Activism

Pills Emerge Amid Tariff Uncertainty, Activism

By Ronald Orol
|
Published: April 28th, 2025
As the markets face tariff-related volatility, some companies, especially biotechnology and pharmaceuticals companies, are setting up or extending shareholder rights plans, known as poison pills, to discourage unsolicited bidders and activist accumulations.